On April 4, the Nexus Hope Foundation’s Principle Investigator, Dr. John Cassidy, gave a presentation titled, “Impact of Zolpidem in the Treatment of Prolonged Disorders of Consciousness” to peers and colleagues at the 2022 American Academy of Neurology (AAN) Annual Meeting in Seattle, Washington.
The Nexus Hope Foundation was established in 2008 as a nonprofit working to make a positive impact in the brain injury community through awareness, research, and enrichment. Complimenting Nexus Health Systems’ work providing a continuum of neurorehabilitative care for patients who have suffered an acquired or traumatic brain injury, the Nexus Hope Foundation provides community engagement and advocacy efforts for brain injury patients and their families.
The Nexus Hope Foundation is also home to a dedicated team of leading healthcare professionals, who conduct groundbreaking research to advance neurorehabilitative care and improve brain injury treatment outcomes.
Dr. Cassidy’s presentation discussed an overview and results of his research evaluating whether FDA-approved sedative-hypnotic drug zolpidem improves arousal and progress toward a fully conscious state in patients with prolonged disorders of consciousness due to acquired brain injury.
During his presentation, Dr. Cassidy discussed his methods of analyzing his hypothesis, as well as his findings and further discussion of patients’ discharge dispositions. The content reported gave valuable insight to fellow researchers and medical professionals in attendance and offered a new perspective in treatment options for patients with acquired brain injury.
The zolpidem research summarized in Dr. Cassidy’s prestigious AAN presentation was one of several studies completed by the research team at the Nexus Hope Foundation. You can read more about those studies here.
For more information about the Nexus Hope Foundation and how you can get involved, visit their website.